Immutep Ltd (PRRUF)
OTHER OTC:PRRUF
Want to see PRRUF full AI Analyst Report?
PRRUF Stock Chart & Stats
$0.06
$0.00(0.00%)
At close: 4:00 PM EST
$0.06
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.33
Previous CloseN/A
Volume70.00
Average Volume (3M)1.42K
Market Cap
$63.38M
Enterprise Value$17.83M
Total Cash (Recent Filing)$99.13M
Total Debt (Recent Filing)$2.16M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,473,721,300
10 Day Avg. Volume4,000
30 Day Avg. Volume1,416
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue2.98
Enterprise Value/Gross Profit-0.57
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$0.12Price Target Upside102.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$19.34M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA low debt-to-equity ratio and healthy equity ratio reduce refinancing risk and provide financial flexibility to fund lengthy clinical programs. This conservative capital structure supports continuity of R&D spending and partnership negotiations over the medium term.
LAG-3 Platform And Diversified PipelineA platform focused on LAG-3 with multiple candidates (eftilagimod alpha, leramilimab and related programs) provides several independent development pathways. Platform breadth increases probability of at least one successful asset and enhances licensing and partnership value over time.
Multiple Funding Channels (collabs & Equity)Access to partner-funded collaborations and the ability to raise equity offer durable funding options for expensive clinical development. Milestone-based partner payments and equity issuance reduce single-source funding risk and help sustain operations through clinical inflection points.
Bears Say
Persistent UnprofitabilityConsistently negative margins across gross, EBIT/EBITDA and net levels indicate the company is not generating profits from operations. Long-term unprofitability necessitates external capital, depresses return on equity, and limits reinvestment without dilutive financing or successful partnerships.
Negative Operating And Free Cash FlowMaterial negative operating and free cash flows create ongoing funding pressure and increase reliance on external capital. Over the medium term this raises dilution risk, can force suboptimal licensing or partnership terms, and constrains the company’s ability to scale multiple trials concurrently.
Small Scale OperationsA very small workforce limits in-house capabilities across clinical development, regulatory, and commercial planning. Such scale typically increases dependence on CROs and partners, can slow execution of multiple programs, and raises operational execution risk during pivotal development stages.
Immutep Ltd News
PRRUF FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest stock price was $0.04 and its highest was $0.33 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is $63.38M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 99 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Feb 24, 2026. The company reported -$0.021 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.001.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -$0.021 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in PRRUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.12 (102.30% Upside)
$0.12 (102.30% Upside)
Blogger Sentiment
Bullish
PRRUF Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
PRRUF Stock 12 Month Forecast
Average Price Target
$0.12
▲(102.30% Upside)
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Ownership Overview
2.21% Insiders
0.08% Mutual Funds
― Other Institutional Investors
97.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---